New checkpoint blockers begin human trials.
Garber
Ken
K
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002453:Cell Cycle / Q000187:drug effects*; D018797:Cell Cycle Proteins / Q000187:drug effects* / Q000378:metabolism; D002986:Clinical Trials as Topic; D004249:DNA Damage / Q000187:drug effects; D004260:DNA Repair / Q000187:drug effects; D015507:Drugs, Investigational / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016193:G1 Phase / Q000187:drug effects; D016195:G2 Phase / Q000187:drug effects; D006801:Humans; D016200:Maturation-Promoting Factor / Q000187:drug effects; D014183:Transplantation, Heterologous; D020687:cdc25 Phosphatases / Q000187:drug effects
D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; D015507:Drugs, Investigational; D016200:Maturation-Promoting Factor; C517009:CDC25C protein, human; D020687:cdc25 Phosphatases